Independent Variable | Coefficient | SE | 95% CI | t statistic | P value | R2 | adj R2 |
---|---|---|---|---|---|---|---|
Additive premiums | |||||||
(1) Basis regression model using all variables untransformed, and additive premiums as the dependent variable | |||||||
  EU Prices | 1.3141259 | 1.00407225 | −1.1427504 – 3.77100219 | 1.30879616 | 0.23849493 | 0.654 | 0.309 |
  Comparable drugs | −0.1535998 | 0.23822837 | −0.7365236 – 0.42932406 | − 0.6447585 | 0.54293375 | ||
  Added benefit | 9034.29827 | 10,716.7639 | −17,188.678 – 35,257.275 | 0.84300618 | 0.4315413 | ||
  AnTC ACT | −0.0486107 | 0.28074618 | −0.7355719 – 0.63835042 | − 0.1731484 | 0.86822835 | ||
  Study design dichotomized | 7356.39568 | 15,843.3671 | −31,410.927 – 46,123.7184 | 0.46432022 | 0.65878822 | ||
  Target population | −1.6576633 | 1.20885101 | −4.6156151 – 1.30028857 | −1.3712718 | 0.21936371 | ||
  Constant | 52,107.00377 | 20,198.79989 | 2682.320947–101,531.6866 | 2.579707906 | 0.04178586* | ||
(2) Basis regression model using all variables untransformed, and log additive premiums as the dependent variable | |||||||
  EU Prices | 0.00001931 | 0.00001709 | −0.00002252 – 0.00006114 | 1.12939086 | 0.30185338 | 0.705 | 0.410 |
  Comparable drugs | −0.00000257 | 0.00000406 | −0.00001249 – 0.00000736 | −0.63303948 | 0.55005850 | ||
  Added benefit | 0.19608572 | 0.18245474 | −0.25036495 – 0.64253639 | 1.07470883 | 0.32381185 | ||
  AnTC ACT | −0.00000076 | 0.00000478 | −0.00001245 –0.00001094 | −0.15849576 | 0.87926624 | ||
  Study design dichotomized | 0.07529218 | 0.26973604 | −0.58472812 – 0.73531249 | 0.27913283 | 0.78951472 | ||
  Target population | −0.00003937 | 0.00002058 | −0.00008973 – 0.00001099 | −1.91280535 | 0.10430143 | ||
  Constant | 10.84596964 | 0.34388803 | 10.00450596–11.68743333 | 31.53924778 | 0.00000007* | ||
(3) Basis regression model with interaction AnTC ACT*Target population, and log additive premiums as the dependent variable | |||||||
  EU Prices | 0.00002490 | 0.00001697 | −0.00001871 – 0.00006852 | 1.46787027 | 0.20206636 | 0.775 | 0.460 |
  Comparable drugs | −0.00000580 | 0.00000467 | −0.00001781 – 0.00000620 | −1.24238121 | 0.26918568 | ||
  Added benefit | 0.04432483 | 0.21293062 | −0.50303075 – 0.59168041 | 0.20816559 | 0.84331349 | ||
  AnTC ACT | −0.00000367 | 0.00000514 | −0.00001688 – 0.00000954 | − 0.71446967 | 0.50689617 | ||
  Target population | −0.00013334 | 0.00007798 | −0.00033380 – 0.00006712 | −1.70982331 | 0.14799077 | ||
  AnTC ACT*Tar. pop | 0.00000000 | 0.00000000 | 0.00000000–0.00000001 | 1.24538235 | 0.26817087 | ||
  Study design dichotomized | −0.04186251 | 0.27475003 | −0.74812996 – 0.66440493 | − 0.15236582 | 0.88485596 | ||
  Constant | 11.71190494 | 0.76927118 | 9.73443041–13.68937947 | 15.22467656 | 0.00002217* | ||
(4) Bivariate regression model using statistical significant variables, and additive premiums as the dependent variable | |||||||
  EU-prices | 1.00815416 | 0.49637946 | −0.09784821 – 2.11415654 | 2.031015043 | 0.069686298 | 0.554 | 0.465 |
  Target population | −1.80975847 | 0.78477917 | −3.55835544 – −0.06116149 | −2.306073507 | 0.043799202* | ||
  Constant | 61,129.98695 | 7879.338538 | 43,573.72662788–78,686.24727887 | 7.7582638 | 0.00001539* | ||
(5) Bivariate regression model using statistical significant variables, and log additive premiums as the dependent variable | |||||||
  EU-prices | 0.00001578 | 0.00000860 | −0.00000338 – 0.00003494 | 1.83493479 | 0.09639450 | 0.606 | 0.528 |
  Target population | −0.00003976 | 0.00001360 | −0.00007005 – − 0.00000946 | −2.92431420 | 0.01518788* | ||
  Constant | 11.02820319 | 0.13649721 | 10.72406846–11.33233792 | 80.79435053 | 0.00000000* | ||
(6) Bivariate Regression model using log EU-prices and target population, and log additive premiums as dependent variable | |||||||
  Log EU-prices | 0.14680259 | 0.06653394 | −0.00144427 – 0.29504945 | 2.20643159 | 0.05187319 | 0.646 | 0.575 |
  Target population | −0.00003672 | 0.00001317 | −0.00006606 – --0.00000738 | −2.788982 | 0.0191532* | ||
  Constant | 9.90990728 | 0.57996394 | 8.61766708–11.20214748 | 17.08710928 | 0.00000001 | ||
(7) Multivariate regression model using statistical significant variables, study design, and log additive premiums as the dependent variable | |||||||
  EU-prices | 0.00000695 | 0.00000928 | −0.00001405 – 0.00002794 | 0.74851855 | 0.47325401 | 0.707 | 0.610 |
  Target population | −0.00004912 | 0.00001344 | −0.00007953 – − 0.00001870 | −3.6531866 | 0.00529125* | ||
  Study design trichotomized | 0.18888016 | 0.10707861 | −0.05334849 – 0.43110881 | 1.76393916 | 0.11156758 | ||
  Constant | 10.71083426 | 0.21852857 | 10.21648828–11.20518023 | 49.01342718 | 0.00000000* | ||
(8) Basis regression model with interaction AnTC*target population, trichotomized study design, and log additive premiums as the dependent variable | |||||||
  EU Prices | 0.00001430 | 0.00001280 | −0.00001859 – 0.00004719 | 1.11734172 | 0.31464184 | 0.878 | 0.708 |
  Comparable drugs | −0.00000489 | 0.00000346 | −0.00001379 – 0.00000400 | −1.41398786 | 0.21649968 | ||
  Added benefit | −0.26610636 | 0.21675823 | −0.82330113 – 0.29108840 | −1.22766442 | 0.27421249 | ||
  AnTC ACT | −0.00000604 | 0.00000394 | −0.00001616 – 0.00000409 | −1.53330417 | 0.18577935 | ||
  Target population | −0.00019253 | 0.00005941 | −0.00034526 – − 0.00003980 | −3.24045751 | 0.02293760* | ||
  AnTC ACT*Tar. pop | 0.0000000029 | 0.00000000 | 0.00000000–0.00000001 | 2.50391081 | 0.05423011* | ||
  Study design trichotomized | 0.29015387 | 0.13996625 | −0.06964081 – 0.64994856 | 2.07302748 | 0.09288142 | ||
  Constant | 11.81575737 | 0.51914558 | 10.48125116–13.15026357 | 22.76000749 | 0.00000304* | ||
Multiplicative premiums | |||||||
(9) Basis regression model using all variables untransformed, and multiplicative premiums as the dependent variable | |||||||
  EU Prices | 0.01863379 | 0.03046329 | −0.0559072 – 0.09317478 | 0.61167992 | 0.56319335 | 0.708 | 0.417 |
  Comparable drugs | −0.0170363 | 0.00722779 | −0.0347221 – 0.00064944 | −2.3570588 | 0.05651068 | ||
  Added benefit | 318.494844 | 325.143866 | −477.10353 – 1114.09322 | 0.97955052 | 0.36513746 | ||
  AnTC ACT | 0.00768265 | 0.00851777 | −0.0131596 – 0.02852487 | 0.90195532 | 0.40183525 | ||
  Study design dichotomized | −606.94617 | 480.68369 | − 1783.1368 – 569.244448 | −1.2626727 | 0.25356019 | ||
  Target population | −0.0694163 | 0.03667623 | −0.1591598 – 0.02032722 | −1.8926775 | 0.10725321 | ||
  Constant | 1329.140422 | 612.8264012 | −170.39176 – 2828.67261 | 2.168869389 | 0.073175976 | ||
(10) Basis regression model using all variables untransformed, and log multiplicative premiums as the dependent variable | |||||||
  EU Prices | 0.00004607 | 0.00009979 | 0.12277548–9.94718239 | 0.46161051 | 0.66062263 | 0.815 | 0.630 |
  Comparable drugs | −0.00005089 | 0.00002368 | −0.00019812 – 0.00029025 | −2.14954836 | 0.07515311 | ||
  Added benefit | 2.23125516 | 1.06511407 | −0.00010883 – 0.00000704 | 2.09485090 | 0.08105271 | ||
  AnTC ACT | −0.00000966 | 0.00002790 | −0.37498507 – 4.83749539 | −0.34604099 | 0.74112304 | ||
  Study design dichotomized | −2.19341764 | 1.57463515 | −0.00007793 – 0.00005862 | −1.39296880 | 0.21305128 | ||
  Target population | −0.00025771 | 0.00012014 | −6.04641104 – 1.65957577 | −2.14498038 | 0.07562852 | ||
  Constant | 5.03497894 | 2.00751141 | −0.00055169 – 0.00003628 | 2.50806990 | 0.04602317* | ||
(11) Basis regression model using all variables untransformed, trichotomized study design, and log multiplicative premiums as the dependent variable | |||||||
  EU Prices | 0.00002793 | 0.00010268 | −0.00022332 – 0.00027919 | 0.27202759 | 0.79471928 | 0.822 | 0.646 |
  Comparable drugs | −0.00004310 | 0.00002491 | −0.00010406 – 0.00001786 | −1.72989859 | 0.13437373 | ||
  Added benefit | 0.81020226 | 1.23677559 | −2.21607858 – 3.83648311 | 0.65509238 | 0.53669959 | ||
  AnTC ACT | −0.00001518 | 0.00002732 | −0.00008202 – 0.00005167 | − 0.55547716 | 0.59865283 | ||
  Study design trichotomized | 1.51393827 | 1.00119466 | −0.93589681 – 3.96377335 | 1.51213179 | 0.18125773 | ||
  Target population | −0.00021019 | 0.00010064 | −0.00045646 – 0.00003607 | −2.08848182 | 0.08176979 | ||
  Constant | 2.41624100 | 2.26119548 | −3.11670503 – 7.94918702 | 1.06856794 | 0.32635841 | ||
(12) Univariate regression model using log AnTC ACT, and log multiplicative premiums as the dependent variable | |||||||
  Log AnTC ACT | −0.931522444 | 0.036401089 | −1.0116407 – − 0.8514042 | −25.59051002 | 0.000000000037* | 0.983 | 0.981 |
  Constant | 10.68460638 | 0.326107398 | 9.96684884–11.4023639 | 32.76407232 | 0.000000000003* | ||
(13) Univariate regression model using log AnTC ACT, trichotomized study design, and log multiplicative premiums as the dependent variable | |||||||
  Log AnTC ACT | −0.9010848 | 0.04282724 | −0.9965099 – − 0.8056598 | −21.03999339 | 0.0000000013* | 0.985 | 0.983 |
  Study design trichotomized | 0.2069238 | 0.16343973 | −0.1572426 – 0.57109022 | 1.266055713 | 0.234191404 | ||
  Constant | 9.947609983 | 0.663086674 | 8.4701608–11.4250592 | 15.00197541 | 0.0000000349* |